MARON
AND MCKENNA et al., ACC/ESC Expert Consensus Document on Hypertrophic
Cardiomyopathy
JACC 2003; 42:
000-000
American
College of Cardiology/European Society of Cardiology Clinical
Expert Consensus Document on Hypertrophic Cardiomyopathy
A
Report of the American College of Cardiology Foundation Task
Force on Clinical Expert Consensus Documents and the European
Society of Cardiology Committee for Practice Guidelines
Preamble
This
document has been developed as a Clinical Expert Consensus
Document (CECD), combining the resources of the American College
of Cardiology Foundation (ACCF) and the European Society of
Cardiology (ESC). It is intended to provide a perspective
on the current state of management of patients with hypertrophic
cardiomyopathy. Clinical Expert Consensus Documents are intended
to inform practitioners, payers, and other interested parties
of the opinion of the ACCF and the ESC concerning evolving
areas of clinical practice and/or technologies that are widely
available or new to the practice community. Topics chosen
for coverage by expert consensus documents are so designed
because the evidence base, the experience with technology,
and/or the clinical practice are not considered sufficiently
well developed to be evaluated by the formal American College
of Cardiology/American Heart Association (ACC/AHA) Practice
Guidelines process. Often the topic is the subject of considerable
ongoing investigation. Thus, the reader should view the CECD
as the best attempt of the ACC and the ESC to inform and guide
clinical practice in areas where rigorous evidence may not
yet be available or the evidence to date is not widely accepted.
When feasible, CECDs include indications or contraindications.
Some topics covered by CECDs will be addressed subsequently
by the ACC/AHA Practice Guidelines Committee.
The
Task Force on Clinical Expert Consensus Documents makes every
effort to avoid any actual or potential conflicts of interest
that might arise as a result of an outside relationship or
personal interest of a member of the writing panel. Specifically,
all members of the writing panel are asked to provide disclosure
statements of all such relationships that might be perceived
as real or potential conflicts of interest to inform the writing
effort. These statements are reviewed by the parent task force,
reported orally to all members of the writing panel at the
first meeting, and updated as changes occur.
Robert
A. Vogel, MD, FACC
Chair, ACCF Task Force on Clinical Expert
Consensus Documents
Werner
W. Klein, MD, FACC, FESC
Chair, ESC Committee for Practice Guidelines
©
2003 by the American College of Cardiology and the European
Society of Cardiology |
